Media stories about Sinovac Biotech (NASDAQ:SVA) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sinovac Biotech earned a news impact score of 0.01 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Sinovac Biotech, Ltd. (SVA) Rating Lowered to Buy at BidaskClub (americanbankingnews.com)
- SINOVAC NOTICE: Rosen Law Firm Reminds Sinovac Biotech Ltd. Investors of Important Deadline in First Filed Class Action – SVA (finance.yahoo.com)
- SVA INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Sinovac Biotech Ltd. and a Lead Plaintiff Deadline of September 1, 2017 (finance.yahoo.com)
Sinovac Biotech (NASDAQ:SVA) traded down 0.59% during midday trading on Friday, reaching $6.78. The company’s stock had a trading volume of 62,340 shares. Sinovac Biotech has a 1-year low of $4.60 and a 1-year high of $6.94. The company has a 50 day moving average of $6.38 and a 200-day moving average of $5.79. The company’s market capitalization is $386.24 million.
A number of brokerages recently commented on SVA. ValuEngine upgraded Sinovac Biotech from a “sell” rating to a “hold” rating in a report on Friday, June 30th. BidaskClub cut Sinovac Biotech from a “strong-buy” rating to a “buy” rating in a report on Friday.
COPYRIGHT VIOLATION WARNING: “Sinovac Biotech (SVA) Receiving Somewhat Favorable News Coverage, Report Finds” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/07/29/sinovac-biotech-sva-earning-somewhat-positive-press-coverage-study-finds-updated-updated-updated.html.
Sinovac Biotech Company Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.